ArticleOpen forum infectious diseases2019
Temporal and Geographic Variation in Antimicrobial Susceptibility and Resistance Patterns of Enterococci: Results From the SENTRY Antimicrobial Surveillance Program, 1997-2016.
Article in Open forum infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 3 syntheses or guidelines pooled it, 108 citations in OpenAlex.
- Hospital-acquired infections caused by enterococci: a systematic review and meta-analysis, WHO European Region, 1 January 2010 to 4 February 2020.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2021Pooled it
- Sex differences in vancomycin-resistant enterococci bloodstream infections-a systematic review and meta-analysis.Biology of sex differences · 2021Pooled it
- Preoperative oral fluoroquinolone antibiotics in elective colorectal surgery to prevent surgical site infections: a systematic review and meta-analysis.Canadian journal of surgery. Journal canadien de chirurgiePooled it
- Genomic Epidemiology, Antimicrobial Resistance, and Virulence of ClinicalAntibiotics (Basel, Switzerland) · 2026Article
- Evaluation of resistance mechanisms and susceptibility testing in Enterococcus spp.: implications of vancomycin-variable isolates and optrA-mediated resistance.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Article
- Growth-dependent tRNA Reprogramming and Codon Bias Link Translation to Metabolic State inbioRxiv : the preprint server for biology · 2026Article
- Performance of EUCAST disc diffusion and supplementary methods to detect reduced susceptibility to linezolid in enterococci- the NordicAST LRE-study.The Journal of antimicrobial chemotherapy · 2026Article
- Ceftobiprole alone versus ampicillin-ceftriaxone against borderline-penicillin-resistant, ampicillin-susceptible, and vancomycin-resistantAntimicrobial agents and chemotherapy · 2026Article
- Distribution of Virulence Factors in Vancomycin-Resistant Enterococci Isolated from Clinical and Intestinal Samples.Microorganisms · 2025Article
- High-resolution genomic and molecular characterization of vancomycin-resistant enterococci from hospitalized patients in a tertiary care center in Riyadh, Saudi Arabia.Scientific reports · 2025Article
- Antimicrobial resistance interventions in Latin America and the Caribbean: a scoping review of reported interventions between 2018-2024.Antimicrobial resistance and infection control · 2025Article
- Cefuroxime axetil dosing regimens and probability of target attainment in adults and children.British journal of clinical pharmacology · 2025Article
- Unlocking the Potential ofMicroorganisms · 2025Article
- Do Aminopenicillins Have a Role in Treating Ampicillin-ResistantOpen forum infectious diseases · 2025Article
- Antimicrobial activity of lefamulin against pathogens most commonly causing community-acquired pneumonia: results from the China antimicrobial surveillance network in 2020-2022.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Polymeric Anti-Antibiotic Microparticles to Prevent Antibiotic Resistance Evolution.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- The Evolving Landscape of Infective Endocarditis: Difficult-to-Treat Resistance Bacteria and Novel Diagnostics at the Foreground.Journal of clinical medicine · 2025Review
- The Changes in the Antibiotic Resistance ofJournal of clinical medicine · 2025Article
- Treatment Options for Nosocomial Ventriculitis/Meningitis: A Case Report and Review of the Literature.Pathogens (Basel, Switzerland) · 2024Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe SENTRY Antimicrobial Surveillance Program was established in 1997 and presently encompasses more than 750 000 bacterial isolates from over 400 medical centers worldwide. Among these pathogens, enterococci represents a prominent cause of bloodstream (BSIs), intra-abdominal (IAIs), skin and skin structure, and urinary tract infections (UTIs). In the present study, we reviewed geographic and temporal trends in
methodsFrom 1997 to 2016, a total of 49 491 clinically significant enterococci isolates (15 species) were submitted from 298 medical centers representing the Asia-Pacific (APAC), European, Latin American (LATAM), and North American (NA) regions. Bacteria were identified by standard algorithms and matrix-assisted laser desorption ionization-time of flight mass spectrometry. Susceptibility (S) testing was performed by reference broth microdilution methods and interpreted using Clinical and Laboratory Standards Institute/US Food and Drug Administration and European Committee on Antimicrobial Susceptibility Testing criteria.
resultsThe most common
conclusionsEnterococci remained a prominent gram-positive pathogen in the SENTRY Program from 1997 through 2016. The overall frequency of VRE was 15.4% and increased over time in all monitored regions. Newly released agents with novel mechanisms of action show promising activity against VRE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.